AIIMS, Delhi bags patent for cancer detection system for early and effective identification of prostate cancer.

July 4, 2022

The All-India Institute of Medical Sciences (AIIMS), Delhi has received a patent from the Indian Patent Office for its nanotechnology-based cancer detection system for early and effective identification of cancer.
The order was issued by the patent office after the institution amended its claims and submitted all the required documents in recent months.
The cancer detection system comprises an antibody against a target protein bio marker selected from microseminoprotein-beta, a prostate specific antigen (PSA) or combination thereof, a Quantum Dot conjugated with the antibody specific to target protein biomarkers.
It also provides novel immuno-nano-fluorescent-assay, which has advantages over conventional Elisa based detection systems in terms of higher prognosis, specificity, sensitivity, robustness, portability, less time consuming and cost effectiveness.
According to the institution, the prostate cancer is the second most common cause of cancer death in men globally as well as in India that killed an estimated three lakh men around the world in the year 2010.
Out of the prostate cancers detected, almost 85 per cent of the cases were detected in the late stages in the country, mostly in the third or the fourth stages.
The report was released based on testing of almost 4.46 lakh samples tested across the country.
Higher levels of abnormal prostate cancer results were identified in men with more than 85 years of age, while the second highest were in men between 61 to 85 years.